Click Therapeutics, Inc.

Click Therapeutics develops, validates, and commercializes prescription digital therapeutics (PDTs) that function as medical treatments delivered through software. The company operates at the intersection of neuroscience and technology, creating FDA-cleared digital treatments for conditions including depression, migraine, and schizophrenia that are prescribed by physicians and delivered via smartphone applications.

The company has pioneered the concept of Software-Enhanced Drugs™ through its Click SE™ platform, which combines traditional pharmacotherapy with software-based interventions to deliver enhanced clinical outcomes compared to medication alone. Click Therapeutics has successfully navigated FDA regulatory pathways, achieving clearance for CT-152 (Rejoyn™) for major depressive disorder and CT-132 for episodic migraine prevention, with additional programs in clinical development.

Click Therapeutics collaborates with major pharmaceutical companies including Otsuka Pharmaceutical and Boehringer Ingelheim to develop and commercialize digital therapeutic solutions. The company maintains an active research program with multiple peer-reviewed publications and has demonstrated positive results in Phase 3 clinical trials for several of its digital therapeutic candidates.

Choose Click Therapeutics when you need a partner with proven experience developing FDA-cleared prescription digital therapeutics with rigorous clinical validation. The company excels in scenarios requiring deep neuroscience expertise, pharmaceutical collaboration, and navigation of complex regulatory pathways for software-based medical treatments.

Expect a science-first approach grounded in clinical trials, peer-reviewed research, and established regulatory processes. Click Therapeutics is particularly well-suited for organizations seeking to develop digital therapeutics that complement traditional pharmaceutical interventions or require prescription-level clinical evidence and FDA clearance.

Click Therapeutics operates exclusively in the healthcare sector, specializing in prescription digital therapeutics for mental health and neurological conditions. The company demonstrates deep healthcare expertise through FDA regulatory clearances, completed Phase 3 clinical trials, and partnerships with major pharmaceutical companies.

Their healthcare focus encompasses major depressive disorder, episodic migraine, schizophrenia, and breast cancer-related conditions, with all products requiring physician prescription and designed to FDA medical device standards. The company's approach to PDURS (Prescription Drug-Use Related Software) and software-enhanced drug therapies positions them at the forefront of regulatory innovation in digital healthcare.

Pharmaceutical companies developing combination therapies that integrate software with traditional drugs, digital health companies pursuing prescription digital therapeutic pathways requiring FDA clearance, health systems implementing evidence-based digital treatments for mental health and neurological conditions, and research organizations conducting clinical trials for software-based medical interventions in psychiatry and neurology.